Objective
We sought to determine if maternal bupropion treatment in early pregnancy is associated
with congenital heart defects in the infant.
Study Design
We conducted a retrospective case-control study of birth defects risk factors. Data
on 6853 infants with major heart defects were compared with 5869 control infants born
in 1997–2004. Bupropion exposure was defined as any reported use between 1 month before
and 3 months after conception.
Results
Mothers of infants with left outflow tract heart defects were more likely to have
reported taking bupropion than mothers of control infants (adjusted odds ratio, 2.6;
95% confidence interval, 1.2–5.7; P = .01).
Conclusion
We identified a positive association between early pregnancy bupropion use and left
outflow tract heart defects; however, the magnitude of the observed increased risk
was small. Nevertheless, further studies are needed to confirm these results.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of Obstetrics & GynecologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Bupropion: a review of its mechanism of antidepressant activity.J Clin Psychiatry. 1995; 56: 395-401
- A comparison of sustained-release bupropion and placebo for smoking cessation.N Engl J Med. 1997; 337: 1195-1202
- Pharmacologic treatment of depression during pregnancy.JAMA. 1999; 282: 1264-1269
- Smoking patterns and use of cessation interventions during pregnancy.Am J Prev Med. 2008; 35: 327-333
- Recommendations for the use of pharmacological smoking cessation strategies in pregnant women.CNS Drugs. 2007; 21: 983-993
GlaxoSmithKline Bupropion Pregnancy Registry. Final report: 1 September 1997 through 31 March 2008. Registry Report. Wilmington, NC, 2008.
- Bupropion (amfebutamone): caution during pregnancy.Prescrire Int. 2005; 14: 225
- Bupropion in pregnancy and the prevalence of congenital malformations.Pharmacoepidemiol Drug Saf. 2007; 16: 474-484
- The National Birth Defects Prevention Study.Public Health Rep. 2001; 116: 32-40
- National Birth Defects Prevention Study.Birth Defects Res A Clin Mol Teratol. 2007; 79: 714-727
- National Birth Defects Prevention Study.Arch Pediatr Adolesc Med. 2007; 161: 745-750
- PHACE syndrome: the association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities.Arch Dermatol. 1996; 132: 307-311
- National Birth Defects Prevention Study.N Engl J Med. 2007; 256: 2684-2692
- Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005.J Pediatr. 2008; 153: 807-813
- Echocardiographic evaluation of asymptomatic parental and sibling cardiovascular anomalies associated with congenital left ventricular outflow tract lesions.Pediatrics. 2004; 114: 691-696
- Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study.Am J Obstet Gynecol. 2005; 192: 932-936
- Preclinical toxicology of bupropion: an overview.J Clin Psychiatry. 1983; 44: 60-62
- Paroxetine and fluoxetine in pregnancy: a prospective, multicenter, controlled, observational study.Br J Clin Pharmacol. 2008; 66: 695-705
- First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.N Engl J Med. 2007; 356: 2675-2683
- Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations.Birth Defects Res A Clin Mol Teratol. 2007; 79: 301-308
- First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.Birth Defects Res B Dev Reprod Toxicol. 2007; 80: 18-27
- Paroxetine in the first trimester and the prevalence of congenital malformations.Pharmacoepidemiol Drug Saf. 2007; 16: 1075-1085
- Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations.Epidemiology. 2006; 17: 701-704
Article info
Publication history
Published online: April 26, 2010
Accepted:
February 8,
2010
Received in revised form:
December 10,
2009
Received:
October 9,
2009
Footnotes
Cite this article as: Alwan S, Reefhuis J, Botto LD, et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 2010;203:52.e1-6.
The National Birth Defects Prevention Study is funded by the Centers for Disease Control and Prevention.
The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Identification
Copyright
© 2010 Mosby, Inc. Published by Elsevier Inc. All rights reserved.
